Hypofractionation for clinically localized prostate cancer

Seminars in Radiation Oncology

Volumn 23, Issue 3, 2013, Pages 191-197

  Cabrera, Alvin R ^a   Lee, W Robert ^a  

^a DUKE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER LOCALIZATION; CANCER RADIOTHERAPY; FOLLOW UP; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SAMPLE SIZE;

DOSE FRACTIONATION; HUMANS; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84878820384     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2013.01.005     Document Type: Review

References (22)

1. Coutard H. Roentgentherapy of epitheliomas of the tonsillar region, hypopharynx, and larynx from 1920 to 1926. Am J Roentgenol 1932, 28:313-331.
2. Withers H.R. Biologic basis for altered fractionation schemes. Cancer 1985, 55:2086-2095.
3. Fowler J.F. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989, 62:679-694.
4. Daşu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?. Clin Oncol (R Coll Radiol) 2007, 19:289-301.
5. Garcia-Barros M., Paris F., Cordon-Cardo C., et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003, 300:1155-1159.
6. Lukka H., Hayter C., Julian J.A., et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005, 23:6132-6138.
7. Yeoh E.E., Botten R.J., Butters J., et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: Final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 2011, 81:1271-1278.
8. Arcangeli G., Saracino B., Gomellini S., et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010, 78:11-18.
9. Burman C., Kutcher G.J., Emami B., et al. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys 1991, 21:123-135.
10. Arcangeli S., Strigari L., Gomellini S., et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012, 84:1172-1178.
11. Pollack A., Hanlon A.L., Horwitz E.M., et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 2006, 64:518-526.
12. Pollack A., Walker G., Buyyounouski M., et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2011, 81:S1. (abstract).
13. Kuban D.A., Nogueras-Gonzalez G.M., Hamblin L., et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. Int J Radiat Oncol Biol Phys 2010, 78:S58-S59. (abstract).
14. Dearnaley D., Syndikus I., Sumo G., et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: Preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012, 13:43-54.
15. Kupelian P.A., Willoughby T.R., Reddy C.A., et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007, 68:1424-1430.
16. Madsen B.L., Hsi R.A., Pham H.T., et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results. Int J Radiat Oncol Biol Phys 2007, 67:1099-1105.
17. King C.R., Brooks J.D., Gill H., et al. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82:877-882.
18. Friedland J.L., Freeman D.E., Masterson-McGary M.E., et al. Stereotactic body radiotherapy: An emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat 2009, 8:387-392.
19. Katz A.J., Santoro M., Ashley R., et al. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 2010, 10:1.
20. McBride S.M., Wong D.S., Dombrowski J.J., et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: Preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 2012, 118:3681-3690.
21. Boike T.P., Lotan Y., Cho L.C., et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 2011, 29:2020-2026.
22. Ritter M.A., Forman J.D., Kupelian P.A., et al. A phase I/II trial of increasingly hypofractionated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2009, 75:S80-S81. (abstract).